MyFinsight
Home
Blog
About
Contact
Proceeds from maturities
of marketable...
$57,029K
Proceeds from exercise of
stock options
$605K
Other
$56K
Proceeds from exercise of
warrants
$1K
Net cash provided by
investing activities
$16,153K
Net cash provided by
(used in) financing...
$462K
Canceled cashflow
$40,876K
Canceled cashflow
$200K
Net change in cash,
cash equivalents and...
-$13,329K
Canceled cashflow
$16,615K
Stock-based compensation
expense
$2,671K
something is missing
$1,531K
Reduction in carrying
amount of right-of-use...
$1,441K
Prepaid expenses and
other current and...
-$122K
Other
$30K
something is missing
-$117,008K
Purchases of marketable
securities
$40,812K
Purchases of property and
equipment, net
$64K
Payments for repurchase
of common stock for...
$200K
Net cash used in
operating activities
-$29,944K
Canceled cashflow
$5,795K
Total operating
expenses
-$83,071K
Canceled cashflow
$33,937K
Net loss
-$25,129K
Accrued expenses and
other current...
-$3,522K
Deferred revenue
-$2,769K
Canceled cashflow
$83,071K
Operating lease liability
-$1,536K
Depreciation and
amortization expense
-$1,127K
Net accretion of
discounts on marketable...
$1,089K
Accounts receivable
$482K
Accounts payable
-$85K
research and development
$24,606K
General and
administrative
$9,331K
something is missing
-$84,508K
Revenue from
collaboration agreements
-$18,779K
Non-operating income
-$4,913K
Back
Back
Cash Flow
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)
source: myfinsight.com